Your browser is no longer supported. Please, upgrade your browser.
VIE Viela Bio, Inc. daily Stock Chart
Viela Bio, Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own1.20% Shs Outstand41.59M Perf Week39.23%
Market Cap1.37B Forward P/E- EPS next Y-2.80 Insider Trans- Shs Float41.08M Perf Month71.35%
Income-57.20M PEG- EPS next Q-1.08 Inst Own- Short Float1.07% Perf Quarter-
Sales20.00M P/S68.42 EPS this Y- Inst Trans- Short Ratio2.26 Perf Half Y-
Book/sh-293.22 P/B- EPS next Y-28.40% ROA- Target Price33.67 Perf Year-
Cash/sh4.54 P/C7.24 EPS next 5Y- ROE- 52W Range18.20 - 33.43 Perf YTD40.54%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-1.59% Beta-
Dividend %- Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low80.77% ATR2.45
Employees80 Current Ratio9.40 Sales Q/Q- Oper. Margin- RSI (14)- Volatility11.81% 9.78%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.50 Prev Close33.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume194.51K Price32.90
Recom1.70 SMA2048.29% SMA5050.53% SMA20050.53% Volume97,182 Change-0.30%
Oct-28-19Initiated Morgan Stanley Overweight $25
Oct-28-19Initiated Guggenheim Buy $44
Oct-28-19Initiated Goldman Buy $32
Oct-28-19Initiated Cowen Outperform
Oct-11-19 05:01PM  Gates-Backed Vir Biotechnology Flops in Trading Debut Bloomberg
Oct-09-19 06:00AM  Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions GlobeNewswire -9.22%
Oct-07-19 04:05PM  Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -5.97%
Oct-03-19 02:49PM  UPDATE: Viela Bio jumps 27% in trading debut MarketWatch
Oct-02-19 09:54PM  Viela Bio Announces Pricing of Initial Public Offering GlobeNewswire
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjogren's syndrome; and VIB7734 for cutaneous lupus erythematosus. The company has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan and Other Asia Regions. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.